Interviews

Molly Burich: How to Improve Biosimilar Uptake

May 5th 2020

Molly Burich, MS, head of public policy at Boehringer Ingelheim, discusses several tactics that would help increase biosimilar uptake in the United States and get around current obstacles during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Part 1: Axinn Patent Attorneys Talk ACA Pushback and the BPCIA

May 4th 2020

Video

Ted Mathias and Stacie Ropka, PhD, patent attorneys and partners at Axinn, Veltrop, and Harkrider LLP, discuss the overall pushback to the Affordable Care Act (ACA) and what that means for the Biologics Price Competition and Innovation Act (BPCIA).

Christine Simmon Talks Uptake Patterns: Biosimilars vs Generics

April 30th 2020

Video

Christine Simmon talks about whether or not biosimilar uptake will happen as rapidly as it did for generics at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.

IPD Analytics Experts Discuss Humira's Influence on Biosimilars

April 29th 2020

Video

Two IPD Analytics pharmacy experts discuss the ever-growing number of Humira (adalimumab) biosimilars, how developers are trying to stand out from the crowd, and the potential for the first-ever interchangeable biosimilar.

IPD Analytics Experts Discuss the Insulin Pipeline

April 27th 2020

Video

Two IPD Analytics pharmacy experts give us their take on the overall biosimilar pipeline, but also on how incoming insulin products are positioned for success.

Molly Burich Discusses the FDA's Interchangeability Guidance Update

April 22nd 2020

Video

Molly Burich, MS, head of public policy at Boehringer Ingelheim (BI), discusses how the FDA's new guidance on interchangeability designation will improve confidence and acceptance for biosimilars during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Molly Burich Discusses the Lack of Interchangeable Biosimilars

April 21st 2020

Video

Molly Burich, MS, head of public policy at Boehringer Ingelheim, discusses the why there currently are no biosimilars with an interchangeability designation during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California..

Will Gatziolis Talks Biosimilar Marketing in a Post-COVID-19 World

April 20th 2020

Video

Will Gatziolis, MBA, an associate principal at ZS, talks how the coronavirus (COVID-19) pandemic will help biosimilar uptake and what manufacturers can do to take advantage of this opportunity.

Surya Singh, MD, Explains How Biosimilar Education Has Reduced Provider Doubt

April 15th 2020

Video

Surya Singh, MD discusses how education efforts have reduced providers’ doubts surrounding the similarity between biosimilars and their reference products at the March 2020 FDA/Federal Trade Commission workshop on anticompetitive practices.

Sarfaraz K. Niazi, PhD, Discusses How COVID-19 May Help Biosimilar Uptake

April 13th 2020

Video

Sarfaraz Niazi, PhD, an adjunct professor of biopharmaceutical Sciences at the College of Pharmacy at the University of Illinois at Chicago, discusses how the COVID-19 (coronavirus) pandemic is affecting drug shortages, challenging the FDA, and creating an greater opportunity for biosimilars down the road.